[Asthma and nasal polyposis: Are biological treatments effective?]

Colak S., Colak M., Mungan D.

Tuberkuloz ve toraks, cilt.69, sa.2, ss.253-260, 2021 (ESCI, Scopus, TRDizin) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 69 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5578/tt.20219816
  • Dergi Adı: Tuberkuloz ve toraks
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.253-260
  • Anahtar Kelimeler: Severe asthma, nasal polyp, type 2 inflammation, biological treatments, CHRONIC RHINOSINUSITIS, DOUBLE-BLIND, MEPOLIZUMAB, PREVALENCE, EFFICACY
  • Ankara Üniversitesi Adresli: Evet

Özet

Chronic rhinosinusitis with nasal polyps often accompanies severe asthma. Uncontrolled nasal polyp does not only impair the quality of life, but also makes it difficult to control the accompanying asthma. Eosinophilic chronic sinusitis dominated by type 2 inflammation is phenotypically manifested by nasal polyps. In recent years, approaches towards phenotype and endotype have developed in patients with chronic sinusitis as well as in asthma; biological treatments come into question in uncontrolled patients with appropriate endotype. Randomized controlled trials conducted on treatments that antagonize the Ig-E, IL-5, and IL-4a pathways in these patients are promising. The effectiveness of biological treatments, which we think will be more involved in clinical practice in the management of nasal polyp patients in the near future, will become clear with the increase in real life data in the literature.